Cerus (NASDAQ:CERS) PT Raised to $4.00 at Cantor Fitzgerald
Cerus (NASDAQ:CERS – Free Report) had its price objective raised by Cantor Fitzgerald from $3.00 to $4.00 in a research report sent to investors on Friday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. A number of other analysts have also commented on CERS. Stephens reiterated an equal weight […]
Source: wkrb13.com